Based on results obtained in PTEN-loss/BRAF-mut melanoma, the authors demonstrated that a combination of OX40 receptor agonists and PI3K inhibitors successfully improves tumor immune response by promoting the proliferation and cytotoxicity of CD8+ T cells at the tumor site [133]. The gene discussed is BRAF; the disease is neoplasm.